Department of Orthopaedics and Trauma Surgery, University of Pisa, Pisa, Italy.
J Surg Oncol. 2022 Sep;126(4):793-797. doi: 10.1002/jso.26976. Epub 2022 Jun 7.
Synovial sarcoma is a rare malignant tumor that generally requires a multidisciplinary therapeutic approach. In this study we report the experience of a single surgeon, evaluating surgical and oncological outcomes of the cases he treated through his 30 years carrier.
We enrolled patients treated surgically between 1988 and 2018. Surgical and medical treatments, as well as surgical and oncological results, were investigated.
One hundred and thirty cases were included. Surgical resection was carried out achieving wide margins in 90% of the cases. At their latest follow-up, 76 patients were continuously disease free, 16 were no evidence of disease, and other 16 were alive with disease. Twenty cases were dead of disease and two dead of other causes. Twenty-five patients (19%) had local recurrence of synovial sarcoma through their postoperative intercourse. Thirty-seven patients (28%) were diagnosed with at least a metastasis during their follow-up. The global survival of our population, at each patient's latest follow-up, was 82%. Cases with tumor size above 5 cm had a significantly higher risk to develop metastasis (p = 0.002).
Synovial sarcoma is a threatening disease and represents a challenge for oncological physicians and surgeons. Early diagnosis and multidisciplinary approach are mandatory to limit the spread of synovial sarcomas, maximizing the effectiveness of surgery and the other treatments.
滑膜肉瘤是一种罕见的恶性肿瘤，通常需要多学科的治疗方法。在本研究中，我们报告了一位外科医生的经验，评估了他在 30 年的职业生涯中治疗的病例的手术和肿瘤学结果。
我们纳入了 1988 年至 2018 年期间接受手术治疗的患者。研究了手术和医疗治疗以及手术和肿瘤学结果。
共纳入 130 例患者。90%的病例行广泛切除。在最近的随访中，76 例患者持续无病，16 例无疾病证据，16 例有疾病但仍存活。20 例患者死于疾病，2 例患者死于其他原因。25 例（19%）患者在术后随访期间局部复发滑膜肉瘤。37 例（28%）患者在随访期间至少诊断出 1 例转移。我们患者的总体生存率，在每个患者的最新随访时，为 82%。肿瘤大小超过 5cm 的病例发生转移的风险显著增加（p=0.002）。
滑膜肉瘤是一种威胁生命的疾病，对肿瘤内科医生和外科医生都是一个挑战。早期诊断和多学科方法是限制滑膜肉瘤扩散、最大限度提高手术和其他治疗效果的必要手段。
